MY184362A - Inhalable nicotine formulations, and methods of making and using thereof - Google Patents

Inhalable nicotine formulations, and methods of making and using thereof

Info

Publication number
MY184362A
MY184362A MYPI2018700899A MYPI2018700899A MY184362A MY 184362 A MY184362 A MY 184362A MY PI2018700899 A MYPI2018700899 A MY PI2018700899A MY PI2018700899 A MYPI2018700899 A MY PI2018700899A MY 184362 A MY184362 A MY 184362A
Authority
MY
Malaysia
Prior art keywords
methods
making
nicotine formulations
dry powder
powder formulations
Prior art date
Application number
MYPI2018700899A
Other languages
English (en)
Inventor
Noe Zamel
Arthur Slutsky
Steven Ellis
Alex Stenzler
Original Assignee
Philip Morris Products Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philip Morris Products Sa filed Critical Philip Morris Products Sa
Publication of MY184362A publication Critical patent/MY184362A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10—Chemical features of tobacco products or tobacco substitutes
    • A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
    • A24B15/36—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances containing a heterocyclic ring
    • A24B15/40—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances containing a heterocyclic ring having only oxygen or sulfur as hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Otolaryngology (AREA)
  • Addiction (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacture Of Tobacco Products (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
MYPI2018700899A 2015-09-16 2016-09-15 Inhalable nicotine formulations, and methods of making and using thereof MY184362A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/856,102 US9585835B1 (en) 2015-09-16 2015-09-16 Inhalable nicotine formulations and methods of making and using the same
PCT/US2016/051963 WO2017048974A1 (en) 2015-09-16 2016-09-15 Inhalable nicotine formulations, and methods of making and using thereof

Publications (1)

Publication Number Publication Date
MY184362A true MY184362A (en) 2021-04-01

Family

ID=58162192

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2018700899A MY184362A (en) 2015-09-16 2016-09-15 Inhalable nicotine formulations, and methods of making and using thereof

Country Status (19)

Country Link
US (1) US9585835B1 (enExample)
EP (1) EP3349599B1 (enExample)
JP (3) JP7575183B2 (enExample)
KR (1) KR102760317B1 (enExample)
CN (1) CN106539794B (enExample)
AU (1) AU2016323317A1 (enExample)
BR (1) BR112018005145B1 (enExample)
CA (1) CA2999082A1 (enExample)
ES (1) ES2997334T3 (enExample)
HK (1) HK1258016A1 (enExample)
IL (1) IL258143A (enExample)
MX (1) MX394985B (enExample)
MY (1) MY184362A (enExample)
PH (1) PH12018500544A1 (enExample)
PL (1) PL3349599T3 (enExample)
RU (1) RU2719228C2 (enExample)
UA (1) UA126849C2 (enExample)
WO (1) WO2017048974A1 (enExample)
ZA (1) ZA201801569B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9968125B2 (en) * 2015-01-09 2018-05-15 Philip Morris Products S.A. Nicotine—diketopiperazine microparticle formulations and methods of making the same
US11224594B2 (en) * 2015-09-16 2022-01-18 Philip Morris Products S.A. Nicotine formulations and methods of making and using the same
US10149844B2 (en) 2015-09-16 2018-12-11 Philip Morris Products S.A. Inhalable nicotine formulations, and methods of making and using thereof
MX385972B (es) * 2016-06-30 2025-03-18 Philip Morris Products Sa Partículas y composiciones de nicotina.
JP7680823B2 (ja) * 2017-03-07 2025-05-21 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム 吸入可能なニコチン製剤、およびその作製および使用方法
WO2019003118A1 (en) 2017-06-28 2019-01-03 Philip Morris Products S.A. CONTAINER WITH PARTICLES FOR USE WITH INHALER
GB201817868D0 (en) * 2018-11-01 2018-12-19 Nicoventures Trading Ltd Aerosolised formulation
GB201817862D0 (en) 2018-11-01 2018-12-19 Nicoventures Trading Ltd Aerosolisable formulation
WO2021094160A1 (en) * 2019-11-14 2021-05-20 Philip Morris Products S.A. Improved tobacco flavoured dry powder formulation
CN115697299A (zh) * 2020-06-15 2023-02-03 菲利普莫里斯生产公司 新烟草碱粉末组合物
JP2023540190A (ja) 2020-09-03 2023-09-22 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム 低吸湿性活性粉末組成物
US20220313678A1 (en) * 2021-04-06 2022-10-06 Altria Client Services Llc Spray dried nicotine for inclusion in oral products
US20220313614A1 (en) * 2021-04-06 2022-10-06 Altria Client Services Llc Encapsulated nicotine granules and methods of preparation thereof
CN120500327A (zh) * 2022-10-27 2025-08-15 韩国烟草人参公社 用于吸入的低剂量尼古丁干粉组合物
CN120417888A (zh) * 2022-10-27 2025-08-01 韩国烟草人参公社 用于吸入的尼古丁干粉的制备方法
CN117158443B (zh) * 2023-09-05 2024-03-22 贵州大学 烟碱在制备贝莱斯芽胞杆菌生防作用增强剂中的应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441060A (en) * 1993-02-08 1995-08-15 Duke University Dry powder delivery system
CA2146954C (en) 1995-04-12 2008-06-17 Arthur Slutsky Breath activated nicotine inhalers
AUPN862596A0 (en) * 1996-03-12 1996-04-04 F.H. Faulding & Co. Limited Pharmaceutical compositions
CN1110271C (zh) * 1997-09-22 2003-06-04 株式会社大城 烟草调味剂及其烟草
CA2231968A1 (en) 1998-03-11 1999-09-11 Smoke-Stop, A Partnership Consisting Of Art Slutsky Method of producing a nicotine medicament
US20120042886A1 (en) 1998-03-11 2012-02-23 Hanna Piskorz Method of producing a nicotine medicament and a medicament made by the method
CA2265198C (en) 1998-03-11 2009-01-27 Zamel, Noe Method of producing a nicotine medicament and a medicament made by the method
US6234169B1 (en) 1998-08-14 2001-05-22 Arthur Slutsky Inhaler
ES2395096T3 (es) 1999-06-29 2013-02-08 Mannkind Corporation Purificación y estabilización de agentes farmacéuticos a base de péptidos y proteínas
US8256433B2 (en) 1999-07-16 2012-09-04 Aradigm Corporation Systems and methods for effecting cessation of tobacco use
US6799576B2 (en) 1999-07-16 2004-10-05 Aradigm Corporation System for effecting smoking cessation
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
WO2001049274A2 (en) 1999-12-30 2001-07-12 Chiron Corporation Methods for pulmonary delivery of interleukin-2
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
MXPA03001092A (es) 2000-08-07 2003-09-25 Nektar Therapeutics Al Corp Polvos de proteina de haz de 4 helices secados por rocio, inhalables, que tienen agregacion minimizada.
FR2815987B1 (fr) 2000-10-27 2003-02-28 Michel Petiot Embase enfichable pour poteau ou piquet
JP2002161030A (ja) 2000-11-27 2002-06-04 Unisia Jecs Corp 異なる粒径をもった混合粉体の吸入方法
ITMI20012174A1 (it) * 2001-10-18 2003-04-18 Univ Parma Polvere per somministrazione nasale di farmaci
EP1578422B1 (en) 2002-12-20 2007-04-11 NicoNovum AB A physically and chemically stable nicotine and micorcrystalline cellulose containing particulate material
JP2006522634A (ja) 2003-04-14 2006-10-05 ベクトゥラ・リミテッド 投与効率を向上させるデバイス及び製薬組成
WO2005000267A2 (en) 2003-05-28 2005-01-06 Nektar Therapeutics Spray drying of an alcoholic aqueous solution for the manufacture of a water-insoluble active agentmicroparticle with a partial or complete amino acid and/or phospholipid coat
DK1663168T3 (da) 2003-09-08 2009-06-08 Mcneil Ab Nikotinformuleringer og anvendelse deraf
GB0321607D0 (en) * 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
SE528121C2 (sv) * 2004-03-29 2006-09-05 Mederio Ag Preparering av torrpulver för på förhand uppmätt DPI
GB0410398D0 (en) 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
ATE553074T1 (de) * 2004-05-24 2012-04-15 British American Tobacco Co Molekular geprägte, nitrosaminselektive polymere und verfahren zu deren anwendung
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
NZ564025A (en) * 2005-05-11 2012-03-30 Vector Tobacco Inc Reduced risk tobacco products and methods of making same
GB0523576D0 (en) * 2005-11-18 2005-12-28 Theradeas Ltd Drug composition and its use in therapy
US20070178166A1 (en) 2005-12-15 2007-08-02 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
CA2648291A1 (en) 2006-04-04 2007-11-01 Stc.Unm Swellable particles for drug delivery
FI20060428L (fi) * 2006-05-03 2007-11-04 Esko Kauppinen Pintamodifioidut aerosolihiukkaset, menetelmä ja laite niiden tuottamiseksi sekä jauheet ja dispersiot jotka sisältävät kyseisiä hiukkasia
EP2086317A4 (en) * 2006-12-01 2010-03-03 Aradigm Corp NICOTINE FORMULATIONS, KITS AND SYSTEMS AND METHOD FOR THEIR USE
GB0709811D0 (en) * 2007-05-22 2007-07-04 Vectura Group Plc Pharmaceutical compositions
GB0712308D0 (en) 2007-06-25 2007-08-01 Kind Group Ltd An inhalable composition
GB0801876D0 (en) * 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
GB0905840D0 (en) * 2009-04-06 2009-05-20 Sagentia Ltd Apparatus and methods
US20110268809A1 (en) 2010-04-28 2011-11-03 Paul Andrew Brinkley Nicotine-Containing Pharmaceutical Compositions
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
US20130017259A1 (en) * 2011-07-06 2013-01-17 The Parkinson's Institute Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
RS58456B1 (sr) * 2011-08-01 2019-04-30 Univ Monash Postupak i formulacije za inhalaciju
GB201113662D0 (en) 2011-08-08 2011-09-21 Prosonix Ltd Pharmaceutical compositions
US9907748B2 (en) 2011-10-21 2018-03-06 Niconovum Usa, Inc. Excipients for nicotine-containing therapeutic compositions
US20130177646A1 (en) 2012-01-05 2013-07-11 Mcneil Ab Solid Nicotine-Comprising Dosage Form with Reduced Organoleptic Disturbance
US9763928B2 (en) 2012-02-10 2017-09-19 Niconovum Usa, Inc. Multi-layer nicotine-containing pharmaceutical composition
US9056057B2 (en) 2012-05-03 2015-06-16 Kala Pharmaceuticals, Inc. Nanocrystals, compositions, and methods that aid particle transport in mucus
GB201215273D0 (en) * 2012-08-28 2012-10-10 Kind Consumer Ltd Nicotine composition
US20140088045A1 (en) * 2012-09-21 2014-03-27 Basil Rigas Product comprising a nicotine-containing material and an anti-cancer agent
US20140166027A1 (en) 2012-12-14 2014-06-19 Richard C. Fuisz Enhanced Delivery of Nicotine, THC, Tobacco, Cannabidiol or Base Alkaloid from an Electronic Cigarette or Other Vapor Producing Device Through Use of an Absorption Conditioning Unit
US20140261474A1 (en) 2013-03-15 2014-09-18 Aradigm Corporation Methods for inhalation of smoke-free nicotine
KR20190075168A (ko) * 2014-04-08 2019-06-28 필립모리스 프로덕츠 에스.에이. 니코틴 제형 및 이의 제조방법
CA2943459C (en) 2014-04-28 2023-05-02 Philip Morris Products S.A. Nicotine powder inhaler
CN106170313B (zh) 2014-04-28 2020-11-10 菲利普莫里斯生产公司 带香味尼古丁粉末吸入器
FR3035826B1 (fr) * 2015-05-07 2018-11-16 Saint-Gobain Glass France Vitrage de vehicule comprenant une platine pour la fixation de plusieurs accessoires, platine et procede de fixation.
US11224594B2 (en) * 2015-09-16 2022-01-18 Philip Morris Products S.A. Nicotine formulations and methods of making and using the same

Also Published As

Publication number Publication date
PL3349599T3 (pl) 2025-03-24
CN106539794B (zh) 2020-05-15
PH12018500544A1 (en) 2018-09-24
EP3349599C0 (en) 2024-11-20
UA126849C2 (uk) 2023-02-15
US9585835B1 (en) 2017-03-07
AU2016323317A1 (en) 2018-04-12
US20170071856A1 (en) 2017-03-16
ZA201801569B (en) 2019-01-30
HK1258016A1 (zh) 2019-11-01
ES2997334T3 (en) 2025-02-17
MX394985B (es) 2025-03-24
CN106539794A (zh) 2017-03-29
JP7575183B2 (ja) 2024-10-29
EP3349599A1 (en) 2018-07-25
MX2018003272A (es) 2018-08-16
WO2017048974A1 (en) 2017-03-23
RU2018113460A3 (enExample) 2019-10-18
BR112018005145B1 (pt) 2022-05-03
EP3349599A4 (en) 2019-04-17
RU2018113460A (ru) 2019-10-18
IL258143A (en) 2018-05-31
JP2024086897A (ja) 2024-06-28
CA2999082A1 (en) 2017-03-23
KR20180077150A (ko) 2018-07-06
WO2017048974A8 (en) 2018-04-12
RU2719228C2 (ru) 2020-04-17
EP3349599B1 (en) 2024-11-20
KR102760317B1 (ko) 2025-02-03
JP2022097639A (ja) 2022-06-30
JP2018528966A (ja) 2018-10-04
BR112018005145A2 (pt) 2018-12-11

Similar Documents

Publication Publication Date Title
PH12018500544A1 (en) Inhalable nicotine formulations, and methods of making and using thereof
ZA202004557B (en) Modulatory polynucleotides
MX2019010263A (es) Formulaciones de nicotina inhalables y metodos de fabricacion y uso de las mismas.
MX2023010042A (es) Polinucleotidos moduladores.
SG11202011761XA (en) Nicotine formulation
DK3720496T3 (en) Solid oral nicotine formulation
IL264049A (en) Compounds, preparations and methods for treating the disease
IL264156A (en) Compounds, preparations and methods for treating the disease
PH12017500762A1 (en) Proflavor delivery particles
IL266047A (en) Methods and preparations for the treatment of Fabry disease
TW201613901A (en) New compounds
EP3129024A4 (en) Nicotine formulations and methods of making the same
IL258139A (en) Nicotine compositions and methods for their preparation and use
AU201812272S (en) Nicotine Inhaler
IL256350A (en) Compositions and methods for the treatment of substance use disorders, addiction, and psychiatric disorders
MX2018003563A (es) Nuevos compuestos.
MY186229A (en) A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
MX2019002057A (es) Formas solidas de mesilato de cenicriviroc y procesos para elaborar formas sólidas de mesilato de cenicriviroc.
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
EA036036B1 (ru) Композиции, содержащие циклоспорин
MX2016008150A (es) Formulaciones de berberina y usos de las mismas.
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
MX370897B (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades,
AU201812268S (en) Nicotine Inhaler